Yesterday afternoon, the Secretary of the Beijing Municipal Committee, Yin Li, met with Frédéric Oudéa, Chairman of the French Sanofi Group, and Paul Hudson, CEO. Yin Li expressed appreciation for Sanofi's long-standing bullish stance on china and investment in peking, stating that he hopes Sanofi will accelerate project construction in the city, expand the introduction of new drugs, and share opportunities in china's large health market; strengthen partnerships with local pharmaceutical companies, research institutes, and clinical trial institutions, deepen cross-industry cooperation in the field of ai, and jointly expand new industrial tracks; actively play a role in promoting exchanges in various fields between china and france. Beijing will continuously enhance the marketization, legalization, convenience, and internationalization of the business environment to provide solid service support for companies developing in peking. After the meeting, the Municipal Bureau of Economy and Information Technology, the Economic Development Zone, and relevant personnel from Sanofi (China) signed a memorandum of cooperation. Sanofi Group will invest approximately 1 billion euros to build an insulin production base in the Economic Development Zone, focusing on serving the insulin medication needs of local diabetes patients. This base marks the first production of active pharmaceutical ingredients for biopharmaceuticals by a multinational pharmaceutical company in china and sets a record for Sanofi's largest single investment in the country.